These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25741645)

  • 1. Polio inactivated vaccine costs into routine childhood immunization in Brazil.
    Sartori AM; Vicentine MP; Gryninger LC; Soárez PC; Novaes HM
    Rev Saude Publica; 2015; 49():8. PubMed ID: 25741645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program.
    Domingues CM; de Fátima Pereira S; Cunha Marreiros AC; Menezes N; Flannery B
    J Infect Dis; 2014 Nov; 210 Suppl 1(0 1):S143-51. PubMed ID: 25316829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives.
    Mascareñas A; Salinas J; Tasset-Tisseau A; Mascareñas C; Khan MM
    Public Health; 2005 Jun; 119(6):542-9. PubMed ID: 15826896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [On the viability of introducing the inactivated polio vaccine in Colombia].
    Alvarez FP; Mojica JA; Espinal C; Debbag R
    Rev Panam Salud Publica; 2011 May; 29(5):383-4; author reply 384-6. PubMed ID: 21709946
    [No Abstract]   [Full Text] [Related]  

  • 8. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economic impact of introducing the injectable inactivated polio vaccine in Colombia].
    Alvis N; De la Hoz F; Narváez J
    Rev Panam Salud Publica; 2010 May; 27(5):352-9. PubMed ID: 20602069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Future Use, Costs, and Value of Poliovirus Vaccines.
    Thompson KM; Kalkowska DA
    Risk Anal; 2021 Feb; 41(2):349-363. PubMed ID: 32645244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.
    Chen S; Zhao Y; Yang Z; Li Y; Shi H; Zhao T; Yang X; Li J; Li G; Wang J; Ying Z; Yang J
    Hum Vaccin Immunother; 2022 Dec; 18(1):2024063. PubMed ID: 35044877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper.
    Wkly Epidemiol Rec; 2010 Jun; 85(23):213-28. PubMed ID: 20545051
    [No Abstract]   [Full Text] [Related]  

  • 14. Projection of Costs of Polio Eradication Compared to Permanent Control.
    Zimmermann M; Hagedorn B; Lyons H
    J Infect Dis; 2020 Feb; 221(4):561-565. PubMed ID: 31565733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global "switch".
    Gamage D; Ginige S; Palihawadana P
    WHO South East Asia J Public Health; 2018 Sep; 7(2):79-83. PubMed ID: 30136665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia.
    Tucker AW; Isaacs D; Burgess M
    Aust N Z J Public Health; 2001 Oct; 25(5):411-6. PubMed ID: 11688618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
    Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
    MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception.
    Martini Rodrigues CC; Fernandes EG; Dos Santos PP; Eguti RY; Pedroso-de-Lima AC; da Silva GT; Sartori AMC
    Hum Vaccin Immunother; 2022 Nov; 18(5):2063594. PubMed ID: 35439100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.